MX2024004393A - Nuevo anticuerpo monoclonal nav1.7. - Google Patents
Nuevo anticuerpo monoclonal nav1.7.Info
- Publication number
- MX2024004393A MX2024004393A MX2024004393A MX2024004393A MX2024004393A MX 2024004393 A MX2024004393 A MX 2024004393A MX 2024004393 A MX2024004393 A MX 2024004393A MX 2024004393 A MX2024004393 A MX 2024004393A MX 2024004393 A MX2024004393 A MX 2024004393A
- Authority
- MX
- Mexico
- Prior art keywords
- monoclonal antibody
- novel
- chain variable
- variable region
- specific
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Pain & Pain Management (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Dermatology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021178982 | 2021-11-01 | ||
| JP2022005967 | 2022-01-18 | ||
| PCT/JP2022/040580 WO2023074888A1 (ja) | 2021-11-01 | 2022-10-31 | 新規なNav1.7モノクローナル抗体 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2024004393A true MX2024004393A (es) | 2024-04-30 |
Family
ID=86159498
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024004393A MX2024004393A (es) | 2021-11-01 | 2022-10-31 | Nuevo anticuerpo monoclonal nav1.7. |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20250163145A1 (https=) |
| EP (1) | EP4428239A4 (https=) |
| JP (1) | JP7457880B2 (https=) |
| KR (1) | KR102753603B1 (https=) |
| AU (1) | AU2022377536B2 (https=) |
| CA (1) | CA3236404A1 (https=) |
| CO (1) | CO2024003915A2 (https=) |
| IL (1) | IL311683B2 (https=) |
| MX (1) | MX2024004393A (https=) |
| MY (1) | MY206945A (https=) |
| TW (1) | TWI867354B (https=) |
| WO (1) | WO2023074888A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024225446A1 (ja) * | 2023-04-28 | 2024-10-31 | 塩野義製薬株式会社 | 新規なNav1.7モノクローナル抗体を含む医薬組成物 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6214973B1 (en) | 1993-11-19 | 2001-04-10 | Chugai Seiyaku Kabushiki Kaisha | Reshaped human antibody to human medulloblastoma cells |
| DE69535243T2 (de) | 1994-07-13 | 2007-05-10 | Chugai Seiyaku K.K. | Gegen menschliches interleukin-8 gerichteter, rekonstituierter menschlicher antikörper |
| EP0962467A4 (en) | 1996-09-26 | 2002-10-30 | Chugai Pharmaceutical Co Ltd | Antibody against human parathormone related peptides |
| CN102781963B (zh) | 2009-10-27 | 2018-02-16 | Ucb医药有限公司 | 功能修饰性NAv1.7抗体 |
| GB0922434D0 (en) | 2009-12-22 | 2010-02-03 | Ucb Pharma Sa | antibodies and fragments thereof |
| MX2015010749A (es) | 2013-03-14 | 2015-11-30 | Regeneron Pharma | Anticuerpos humanos para nav1.7. |
| JP2016529909A (ja) * | 2013-09-05 | 2016-09-29 | デューク ユニバーシティ | Nav1.7抗体及び前記抗体を使用する方法 |
| GB2517953A (en) | 2013-09-05 | 2015-03-11 | Argen X Bv | Antibodies to complex targets |
| JPWO2019230856A1 (ja) * | 2018-05-31 | 2021-06-24 | 塩野義製薬株式会社 | Nav1.7モノクローナル抗体 |
| US20240002497A1 (en) | 2020-11-19 | 2024-01-04 | Merck Sharp & Dohme Llc | Nav1.7 binders |
| WO2024225446A1 (ja) * | 2023-04-28 | 2024-10-31 | 塩野義製薬株式会社 | 新規なNav1.7モノクローナル抗体を含む医薬組成物 |
-
2022
- 2022-10-31 JP JP2023556697A patent/JP7457880B2/ja active Active
- 2022-10-31 MX MX2024004393A patent/MX2024004393A/es unknown
- 2022-10-31 KR KR1020247018286A patent/KR102753603B1/ko active Active
- 2022-10-31 AU AU2022377536A patent/AU2022377536B2/en active Active
- 2022-10-31 IL IL311683A patent/IL311683B2/en unknown
- 2022-10-31 EP EP22887213.1A patent/EP4428239A4/en active Pending
- 2022-10-31 WO PCT/JP2022/040580 patent/WO2023074888A1/ja not_active Ceased
- 2022-10-31 MY MYPI2024001218A patent/MY206945A/en unknown
- 2022-10-31 US US18/705,139 patent/US20250163145A1/en active Pending
- 2022-10-31 CA CA3236404A patent/CA3236404A1/en active Pending
- 2022-10-31 TW TW111141378A patent/TWI867354B/zh active
-
2024
- 2024-03-27 CO CONC2024/0003915A patent/CO2024003915A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR102753603B1 (ko) | 2025-01-13 |
| CA3236404A1 (en) | 2023-05-04 |
| JPWO2023074888A1 (https=) | 2023-05-04 |
| WO2023074888A1 (ja) | 2023-05-04 |
| TWI867354B (zh) | 2024-12-21 |
| EP4428239A4 (en) | 2025-10-29 |
| IL311683B2 (en) | 2026-04-01 |
| JP7457880B2 (ja) | 2024-03-28 |
| IL311683B1 (en) | 2025-12-01 |
| KR20240099394A (ko) | 2024-06-28 |
| MY206945A (en) | 2025-01-21 |
| TW202325739A (zh) | 2023-07-01 |
| AU2022377536A1 (en) | 2024-04-11 |
| EP4428239A1 (en) | 2024-09-11 |
| AU2022377536B2 (en) | 2024-10-24 |
| US20250163145A1 (en) | 2025-05-22 |
| IL311683A (en) | 2024-05-01 |
| CO2024003915A2 (es) | 2024-04-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20210132A1 (es) | Anticuerpos anti-cd3 y usos de estos | |
| PE20200294A1 (es) | Anticuerpos que se unen especificamente a pd-1 y metodos de uso | |
| ZA202006317B (en) | Monoclonal antibody of nerve growth factor and encoding gene and use thereof | |
| PH12022550211A1 (en) | Anti-pd-1 antibody and medical use thereof | |
| NZ738979A (en) | Pd-1 antibodies | |
| EA201791527A1 (ru) | Биспецифические антитела против плазменного калликреина и фактора xii | |
| BR112023004830A2 (pt) | Métodos para tratamento de mieloma múltiplo | |
| PE20221337A1 (es) | Anticuerpos trem2 y usos de estos | |
| ZA202101258B (en) | Anti-mica/b antibodies that block mica/b shedding and methods of use | |
| MX2020012678A (es) | Anticuerpo monoclonal contra nav1.7. | |
| NZ594682A (en) | Fully human antibodies specific to cadm1 | |
| PH12020551661A1 (en) | Anti-pd-l1 antibody and use thereof | |
| NZ755083A (en) | Anti-tnf antibodies, compositions, and methods for the treatment of active psoriatic arthritis | |
| JOP20220309A1 (ar) | أجسام مضادة تستهدف معقد يشتمل على hla-i ومولد ضد جديد غير تقليدية وطرق استخدامها | |
| MX2021001516A (es) | Uso del anticuerpo tim-3 en la preparacion de medicamentos para el tratamiento de tumores. | |
| ZA202305217B (en) | Anti-tigit antibody, and pharmaceutical composition and use thereof | |
| PE20211296A1 (es) | Anticuerpos anti-pmel17 y conjugados de los mismos | |
| ZA202400787B (en) | Pharmaceutical composition and use | |
| AR112563A1 (es) | Anticuerpos monoclonales anti-sortilina útiles en la corrección de un nivel deficiente de progranulina (pgrn) | |
| MX2024004393A (es) | Nuevo anticuerpo monoclonal nav1.7. | |
| ZA202205288B (en) | Humanized antibody and method for using the same | |
| MX2022008421A (es) | Anticuerpo anti-galectina-9 y usos del mismo. | |
| ZA202202380B (en) | Anti-human p40 protein domain antibody and use thereof | |
| MX2023006777A (es) | Composiciones y métodos que comprenden antagonistas de proteína 2 relacionada con frizzled secretada (sfrp2). | |
| PE20231953A1 (es) | Anticuerpos multiespecificos y combinaciones de anticuerpos |